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A B S T R A C T
Multiple sclerosis (MS) is a chronic, immune-mediated, inflammatory disease affecting the white and gray matter
of the central nervous system. Several disease modifying therapies (DMTs) have been shown to significantly
reduce relapse rates, slow disability worsening, and modify the overall disease course of MS. Decision-making
when initiating a DMT should be shared between the patient and physician. Important factors such as prognostic
indicators, safety, patient preferences, adherence, and convenience should also be considered. Treatment
guidelines recommend switching a DMT when a patient experiences breakthrough disease activity, but also for
patients who experience adverse events. Compared with injectable therapies, oral DMTs are often associated
with increased treatment adherence and patient satisfaction, due to a less burdensome route of administration
and greater tolerability. This review will summarize the available scientific evidence for injectable DMTs and the
oral DMT teriflunomide, including considerations for both treatment-naïve patients initiating a DMT and pa-
tients switching from an injectable DMT.
1. Introduction
Multiple sclerosis (MS) is a chronic, inflammatory disease affecting
the white and gray matter of the central nervous system (Compston and
Coles, 2008; Thompson et al., 2018b). While no curative treatment
exists for MS, several disease-modifying therapies (DMTs) significantly
reduce relapse rates, slow disability worsening, and modify the overall
disease course. Injectable DMTs, which include interferon beta (IFNβ)-
1a, IFNβ-1b, and glatiramer acetate (GA), were the first therapies to be
approved for relapsing- remitting MS (RRMS) by the U.S. Food and
Drug Administration and European Medicines Agency in the 1990s, and
are traditionally considered first-line treatments (Bayer HealthCare
Pharmaceuticals Inc., 2018; Biogen Inc., 2016; EMD Serono Inc., 2015;
Marta and Giovannoni, 2012; Teva Pharma, 2018;
Teva Pharmaceuticals USA Inc., 2018). Since then, oral DMTs have
become available. In the U.S., teriflunomide, fingolimod, dimethyl fu-
marate (DMF), and siponimod were approved as first-line therapies,
and cladribine as second-line therapy, in patients with relapsing MS. In
the European Union, teriflunomide and DMF were approved for first-
line use, with fingolimod and cladribine indicated for use in highly
active RRMS (Biogen, 2017; Biogen Netherlands B.V., 2019;
EMD Serono Inc, 2019; EMD Serono Inc, 2019a; Novartis Pharmaceu-
ticals, 2019; Novartis Pharmaceuticals Corp., 2018;
Novartis Europharm Limited, 2019; Sanofi Genzyme, 2019; Sanofi-
Aventis Groupe, 2019).
The importance of early treatment initiation following a clinically
definitive diagnosis of relapsing MS is well established
(Giovannoni et al., 2017; Montalban et al., 2018; MS Coalition, 2018;
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Rae-Grant et al., 2018). Many DMTs are available for treatment-naïve
patients and patients early in their disease course. This review will
summarize the available scientific evidence for one of the oral DMTs,
teriflunomide, compared with injectable DMTs. We further discuss
considerations for treatment-naïve patients initiating a DMT and pa-
tients switching treatment from an injectable DMT to teriflunomide.
2. Teriflunomide and injectable DMTs
2.1. Mechanisms of action and posology
Teriflunomide is an oral immunomodulatory agent taken once daily,
available in 14 mg doses globally and additionally 7 mg in the US
(Table 1). It selectively and reversibly inhibits dihydroorotate dehy-
drogenase (DHODH), a mitochondrial enzyme essential for de novo
pyrimidine synthesis in rapidly dividing lymphocytes. As a result, the
proliferation and function of activated T and B cells are reduced, while
the resting cells of the adaptive immune system are spared
(Arnold et al., 2014). Results from the TERIDYNAMIC study
(NCT01863888) suggest that DHODH inhibition also corrects metabolic
disturbances in T cells, and may promote recovery of an altered T cell
receptor repertoire in autoimmunity (Klotz et al., 2019). Preclinical and
clinical data suggest that teriflunomide also has antiviral properties
(Edwards et al., 2017).
Five preparations of IFNβ are currently available, one of which is a
weekly intramuscular (IM) injection, with the remaining four admini-
strated as subcutaneous (SC) injections at frequencies ranging from
every second day to once every two weeks (see Table 1). IFNβ has
antiviral, immunomodulatory, and antiproliferative properties that may
contribute to its mechanisms of action in MS, including increased ex-
pression of anti-inflammatory cytokines and decreased expression of
proinflammatory cytokines. It may also reduce the trafficking of in-
flammatory cells across the blood–brain barrier and increase nerve
growth factor production, leading to a potential increase in neuronal
survival and repair (Kieseier, 2011).
GA is administered as a SC injection, as either a 20 mg daily dose or
40 mg three-times weekly. It is thought to compete with myelin basic
protein for binding to major histocompatibility complex class II mole-
cules on antigen-presenting cells. GA stimulates expansion of T helper 2
cells which may cross-react with myelin to stimulate release of anti-
inflammatory cytokines. Evidence suggests it may also modulate an-
tigen-presenting cells, CD8+ T cells, Foxp3+ regulatory T cells, and
plasma cells, and promote regulatory B-cell properties (Caporro et al.,
2014; Lalive et al., 2011).
2.2. Efficacy, safety, and tolerability
In addition to route of administration, dose, and convenience, ter-
iflunomide and the injectable DMTs differ in their efficacy, safety, and
tolerability profiles. Treatment outcomes of each DMT have been de-
monstrated in randomized, placebo-controlled trials (Tables 2–5). The
data discussed here are limited to the phase 3 trials from each clinical
program, plus adherence/quality of life (QoL) data from phase 4/ob-
servational real-world studies. When evaluating data from individual
trials, differences in the study design, patient population, time period in
which the study took place, and outcome measures used should be
taken into consideration and cross-trial comparisons should be avoided.
As the studies of GA and several of the IFNβ studies took place over
20 years ago when no approved DMT options were available, patient
populations have since evolved (Zhang et al., 2019). A substantial
downward trend in annualized relapse rate (ARR) in the placebo arms
of phase 3 trials has occurred in this timeframe due to changes in di-
agnostic and study criteria, understanding of MS etiology, and selection
biases. In addition, compared with the IFNβ studies, the time from first
MS symptoms to study inclusion was longer for teriflunomide in the
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mean baseline Expanded Disability Status Scale score was higher, and a
greater percentage of patients had previous DMT use (Table 3).
2.2.1. Efficacy
2.2.1.1. Clinical relapses. The phase 3 placebo-controlled trials were of
2 years duration for the earlier injectable DMTs (GA 20 mg and IFNβ)
and teriflunomide, and 1 year duration for pegylated IFNβ-1a and GA
40 mg. The reduction in ARR was similar among the therapies, ranging
from a 29% to 36% reduction compared with their respective placebo
groups (Calabresi et al., 2014a; Confavreux et al., 2014; Khan et al.,
2013; O'Connor et al., 2011; Panitch et al., 2002; PRISMS Study Group,
1998; The IFNB Multiple Sclerosis Study Group, 1993).
A trial of IFNβ-1b (8 MIU [250 µg]; the approved dose) showed a
significant 34% reduction in ARR over 2 years compared with placebo
(0.84 vs. 1.27; p=0.0001) (The IFNB Multiple Sclerosis Study
Group, 1993). In the PRISMS study, the mean number of relapses after 2
years was 2.56 for placebo, and 1.82 and 1.73 for three-times weekly
IFNβ-1a SC 22 µg and 44 µg, respectively (p<0.005) for a percentage
reduction of 27% with the 22 µg dose and 33% with the 44 µg dose
against placebo (PRISMS Study Group, 1998).
GA 20 mg daily demonstrated a 29% reduction in ARR vs placebo at
Year 2 (0.59 vs. 0.84, p=0.007) (Johnson et al., 1995). For GA 40 mg
(three-times weekly), patients showed a 34% reduction in ARR versus
placebo at Year 1 (0.33 vs 0.51; p<0.0001) (Khan et al., 2013).
Teriflunomide showed significant reductions in ARR across clinical
trials, with similar findings between the phase 3 TEMSO and TOWER
studies. In the core TEMSO study, patients receiving teriflunomide 14
mg experienced a 31.5% relative reduction in ARR over 2 years versus
placebo (0.54 for placebo and 0.37 for teriflunomide; [p<0.001])
(O'Connor et al., 2011). In the TOWER study, patients receiving teri-
flunomide 14 mg experienced a 36.3% relative reduction in ARR over 1
year versus placebo (0.50 for placebo, 0.32 for teriflunomide
[p=0.0001]) (Confavreux et al., 2014). In other phase 3 trials, teri-
flunomide yielded ARRs of 0.22 and 0.25 over 30 months (ASCLEPIOS I
and II; respective ARRs for ofatumumab were 0.11 and 0.10 [p<0.001
between treatments in both studies]) (Hauser et al., 2019) and 0.29
over 108 weeks (OPTIMUM; ARR for ponesimod was 0.20 [p=0.0003
between treatments])(Kappos et al., 2019).
2.2.1.2. Disability. Compared with placebo, significant reductions in
time to confirmed disability worsening were seen for IFNβ-1a (IM, SC,
and pegylated products) and teriflunomide, but not for IFNβ-1b and GA
(Table 2).
Both doses of IFNβ-1a SC demonstrated significantly longer time to
3-month confirmed disability worsening compared with placebo over 2
years (p<0.05); (PRISMS Study Group, 1998). In the ADVANCE study
(NCT00906399), the proportion of patients treated with pegylated
IFNβ-1a who had 12 weeks of confirmed disability worsening at 48
weeks (0.068 in both intervention groups [125 µg every 2 weeks or
every 4 weeks]) was reduced compared with placebo (0.105; p=0.038
for both comparisons) (Calabresi et al., 2014a).
In TOWER, teriflunomide 14 mg reduced the risk of 12-week con-
firmed accumulation of disability (hazard ratio [HR] 0.68 [95% CI
0.47–1.00]; p=0.04) over 1 year compared with placebo
(Confavreux et al., 2014). In TEMSO, the proportion of patients with
12-week confirmed disability worsening over 2 years was 27.3% with
placebo, and 20.2% with teriflunomide 14 mg (p=0.03)
(O'Connor et al., 2011).
2.2.1.3. Magnetic resonance imaging (MRI). Significant reductions in the
number of MRI lesions were seen across all treatments compared with
placebo. In the IFNB Multiple Sclerosis Study, patients treated with
Table 2
Efficacy outcomes from placebo-controlled phase 3 trials of injectable DMTs and teriflunomide.
DMT/Trial Relapse rate Disability MRI
IFNβ-1b (IFNB Multiple Sclerosis Study)
(The IFNB Multiple Sclerosis Study
Group, 1993)
34% reduction in ARR over 2
years (p=0.0001) (primary
endpoint)
29% decrease in EDSS change from baseline
(NS)
No Gd+ lesions outcomes, 59% reduction in N/NE
T2 lesions
IFNβ-1a IM (MSCRG Study) (Jacobs et al.,
1996)
18% reduction in ARR at 2
years (p=0.02)
37% relative reduction in risk of
accumulating disability at the end of 2 years
(p=0.02) (primary endpoint: time to
sustained EDSS worsening)
Mean number of Gd+ lesions: 1.65 placebo; 0.80
treated (p=0.05). Median percent change T2 lesion
volume: −6.5% placebo; −13.2% treated (NS) at 2
years
IFNβ-1a SC (PRISMS) 33% reduction in relapse rate
over 2 years (p<0.001)
Time to sustained disability worsening was
significantly longer (p<0.05) in both IFNβ-
1a treatment groups than in the placebo
group
78% reduction in N/NE T2 lesions at 2 years
(p<0.0001)
Peg-IFNβ-1a (ADVANCE) (Calabresi et al.,
2014a) (NCT00906399)
36% reduction in ARR at 48
weeks (p=0.0007) (primary
endpoint)
38% relative risk reduction in disability
worsening at 48 weeks (p=0.0383)
86% relative reduction in Gd+ lesions (p<0.0001),
67% relative reduction in N/NE T2 lesions
(p<0.0001) at 48 weeks
GA (phase 3 study) (Johnson et al., 1995) 29% reduction in ARR at 2
years vs placebo (ARR = 0.59
vs 0.86, p=0.007)
No disability worsening at 24 months:
75.4% placebo; 78.4% treated (NS)
Not assessed
GA (GALA, except for disability)
(Khan et al., 2013) (NCT01067521)
34% reduction in ARR at 12
months (p<0.0001) (primary
endpoint)
Not assessed for 40 mg. For 20 mg: no
disability worsening at 24 months: 75.4%
placebo; 78.4% treated (NS)
35% reduction in Gd+ lesions (p<0.0001), 30%
reduction in N/NE T2 lesions (p<0.003) at 9
months, post hoc SIENA analysis of the open-label
extension showed early start patients had less GM
volume loss compared with delayed start patients
(−2.01 vs −2.33, p=0.073 [baseline to Month 36];
−1.16 vs −1.53, p=0.015 [Month 12 to 36])
Teriflunomide (TEMSO) (O'Connor et al.,
2011) (NCT00134563)
31.5% relative risk reduction
in ARR at 2 years (p<0.001)
(primary endpoint)
29.8% reduction in risk of 12-week
confirmed disability worsening (p=0.03)
80% reduction in Gd+ lesions (p<0.001), 77%
reduction in N/NE T2 lesions, post-hoc SIENA
analysis showed teriflunomide 14 mg significantly
slowed BVL compared with placebo (33.3% risk
reduction from baseline to Year 2; p=0.0001)
Teriflunomide (TOWER)
(Confavreux et al., 2014)
(NCT00751881)
36.3% relative risk reduction
in ARR at 2 years (p=0.0001)
(primary endpoint)
31.5% reduction in risk of 12-week
confirmed disability worsening (p=0.044)
Not assessed
ARR, annualized relapse rate; BVL, brain volume loss; DMT, disease modifying therapy; EDSS, Expanded Disability Status Scale; GA, glatiramer acetate; Gd+,
gadolinium enhancing; GM, gray matter; IFNβ, interferon beta; IM, intramuscular; MRI, magnetic resonance imaging; N/NE, new or newly enlarging; NS; not
significant; Peg-IFNβ, pegylated interferon beta; SC, subcutaneous.
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IFNβ-1b experienced a 59% reduction in the number of new or
enlarging T2 hyperintense lesions over 2 years (gadolinium-enhancing
[Gd+] lesion outcomes were not investigated) (The IFNB Multiple
Sclerosis Study Group, 1993). In the MSCRG study, mean number of Gd
+ lesions over 2 years was 0.80 in patients receiving IFNβ-1a IM,
compared with 1.65 in patients receiving placebo (p=0.05). The
median percent change in T2 lesion volume was –6.5% for placebo
and –13.2% for IFNβ-1a IM (non-significant) (Jacobs et al., 1996). For
patients receiving IFNβ-1a 44 μg SC, a 78% reduction in new or newly
enlarging T2 lesions compared with placebo was demonstrated at 2
years (p<0.0001) (PRISMS Study Group, 1998); this treatment was
associated with fewer overall active MRI lesions compared with IFNβ-
1a IM (p<0.001 at 24 and 48 weeks) (Panitch et al., 2002).
In the GALA study, patients treated with GA experienced a 45%
reduction in Gd+ lesion counts (p<0.0001) and a 35% reduction in
new or newly enlarging T2 lesion counts (p<0.0001) at 1 year
(Khan et al., 2013). Post-hoc analysis of the open-label extension using
the Structural Image Evaluation using Normalization of Atrophy
(SIENA) technique also showed that patients initiating GA treatment
early had less gray matter volume loss over 36 months compared with
delayed-start patients (Zivadinov et al., 2015).
Gadolinium-enhancing lesion counts were reduced with teri-
flunomide compared with placebo over 108 weeks in both TEMSO
(80.4% reduction; p<0.0001) (Wolinsky et al., 2013), and in the TOPIC
study (NCT00622700) of patients with clinically isolated syndrome
(CIS) (58.5% reduction; p=0.0008) (Miller et al., 2014). T2-hyper-
intense lesion volume was also reduced for teriflunomide compared
with placebo in TEMSO (76.7% reduction; p=0.0004) (Wolinsky et al.,
2013); no significant treatment reduction was found in TOPIC
(Miller et al., 2014). In a post-hoc analysis of TEMSO using SIENA,
teriflunomide 14 mg reduced brain volume loss (BVL) over 2 years
compared with placebo (30.6% relative reduction; p=0.0001)
(Radue et al., 2017). Slowed BVL may underlie the ability of teri-
flunomide to delay disability worsening (Sprenger et al., 2019). Al-
though no effect on gray matter volume was found with teriflunomide
in TEMSO (Wolinsky et al., 2013), data from the TOPIC study showed a
40.2% reduction in the loss of cortical gray matter volume for ter-
flunomide compared with placebo over 2 years (p=0.0416)
(Zivadinov et al., 2017).
2.2.1.4. Comparative efficacy. Some head-to-head trials have been
conducted for first-line therapies (Table 5), but none of the therapies
has consistently demonstrated superior efficacy over others. However,
data suggest superiority of high frequency and high dose IFNβ
treatment compared with lower doses. In the EVIDENCE study
(Panitch et al., 2002) (N=677) three-times weekly IFNβ-1a SC 44 µg
demonstrated superior efficacy in the number of relapse-free patients
(p=0.0005) and active MRI lesions (p<0.001) compared with once-
weekly IFNβ-1a IM 30 µg. Studies of IFNβ-1b SC versus GA (BECOME
[NCT00176592], BEYOND [NCT00099502] (Cadavid et al., 2009;
O'Connor et al., 2009)) and teriflunomide versus three-times weekly
IFNβ-1a SC (TENERE [NCT00883337]) (Vermersch et al., 2014),
showed no differences in primary or secondary outcomes between
comparators. Similarly, IFNβ-1a SC 44 µg and GA did not differ over 96
weeks in the REGARD study (NCT00078338) in time to first relapse or
MRI lesion volume outcomes, but lower Gd-enhancing lesion counts in
IFNβ-1a SC-treated patients were observed (p=0.0002 between
treatments) (Mikol et al., 2008).
2.2.2. Safety and tolerability
Each treatment has a unique safety and tolerability profile (Table 4).
Patients treated with IFNβ products most frequently reported flu-like
symptoms, fever, headache, nasopharyngitis, nausea, diarrhea, chills,
myalgia, lymphopenia, and injection site reactions. The most com-
monly reported adverse events (AEs) in patients receiving GA were
injection site erythema, subcutaneous lipoatrophy, nasopharyngitis,
injection site pain, and headache. In teriflunomide-treated patients, the
most common AEs were alanine aminotransferase (ALT) elevation, hair
thinning, diarrhea, nausea, and paresthesia. In the TENERE study, in-
creased ALT was the most common reason for treatment discontinua-
tion in both IFNβ-1a- and teriflunomide-treated patients, with the
highest frequency of discontinuations due to this AE occurring in the
IFNβ-1a arm (8.9% compared with 3.6% for teriflunomide)
(Vermersch et al., 2014).
For women of reproductive potential, teriflunomide is contra-
indicated for use during pregnancy; GA and IFNβ may be used when the
benefit on MS disease outweighs any potential risk to the fetus, as
neither therapy has been associated with negative pregnancy effects
based on thousands of human exposures (Coyle et al., 2019). For
women planning a pregnancy, or who become pregnant, while being
treated with teriflunomide, an accelerated elimination procedure is
recommended, based on animal data indicating teriflunomide's poten-
tial for fetal harm (Sanofi-Aventis Groupe, 2019;
Sanofi Genzyme, 2019). However, in pregnant women who have been
exposed to injectable DMTs or teriflunomide, pregnancy outcomes were
similar to the general population (Andersen et al., 2018; Coyle et al.,
2014; Herbstritt et al., 2016; Sandberg-Wollheim et al., 2005;
Sandberg-Wollheim et al., 2018; Thiel et al., 2016; Vukusic et al.,
2019).
2.2.3. Adherence, treatment satisfaction, and QoL
Treatment adherence is another important consideration in choice
of DMT as improved adherence may lead to better clinical outcomes
(Gerber et al., 2017; Steinberg et al., 2010; Tan et al., 2011). In real-
world observational studies, proportions of patients with no missed
doses were found to be 66% for GA and 85% for weekly IM IFNβ-1a
(Devonshire et al., 2011). This is consistent with a review of studies that
assessed treatment adherence for injectable DMTs, which reported pa-
tient adherence ranging from as low as 49% up to 87.5% (Menzin et al.,
2013). The proportion of patients ≥80% adherent to teriflunomide was
98% (Coyle et al., 2017).
One factor that may affect treatment adherence is patient satisfac-
tion. An observational, retrospective study of patients on injectable
DMTs using the Treatment Satisfaction Questionnaire for Medication
version 1.4 (TSQM v1.4), in which higher scores indicate greater sa-
tisfaction, found that patients were reasonably satisfied with their
treatment and that the main source of dissatisfaction was the incon-
venience of injections. The highest overall satisfaction for injectable
treatments was reported for IFNβ-1a SC (mean± SD: 72.4± 20.3) and
the lowest for IFNβ-1b SC (61.7±23.7). For the TSQM side effects sub-
scale, GA had the highest score (80.6±22.2) and IFNβ-1a IM the
lowest (63.9±24.6). For the effectiveness sub-scale, patients were
most satisfied with IFNβ-1a SC (70.1± 16.9) and least satisfied with
IFNβ-1b SC (63.2±17.9). For the convenience sub-scale, IFNβ-1a SC
scored highest (69.4± 17.4) and IFNβ-1b scored lowest (55.5± 17.2)
(Fernández et al., 2017).
In the phase 3 TENERE study and the real-world Teri-PRO and
TAURUS MS-I studies, patient-reported treatment satisfaction with
teriflunomide 14 mg using the TSQM was consistent, with particularly
high scores for side effects (93.2 in TENERE and 84.1 in Teri-PRO; side
effects not reported in TAURUS) and convenience (89.9, 90.4, and 90.2,
in the TENERE, Teri-PRO, and TAURUS studies, respectively)
(Coyle et al., 2017; Kallmann et al., 2019; Vermersch et al., 2014). In
the comparative TENERE study, mean TSQM v1.4 scores were sig-
nificantly improved at Week 48 with teriflunomide 14 mg compared
with SC IFNβ-1a for global satisfaction (least squares [LS] mean dif-
ference 7.84; p=0.02), side effects (21.77; p<0.0001), and con-
venience (27.96; p<0.0001) (Vermersch et al., 2014). In patients who
received previous MS treatments in TAURUS MS-I, TSQM v9 values at
24 months improved by 8.1 points for effectiveness, 17.0 points for
convenience, and 15.3 points for global satisfaction (p≤0.001 each)
compared with study entry (Kallmann et al., 2019). Additional
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measures of QoL used in the Teri-PRO study include the Multiple
Sclerosis International Quality of Life and Stern Leisure Activity Scale
(Coyle et al., 2018). Total scores for these measures remained stable
over 48 weeks in patients switching to teriflunomide from other DMTs,
including injectable DMTs (Coyle et al., 2018). Higher treatment sa-
tisfaction with oral treatments such as teriflunomide compared with
injectable DMTs may reflect different adverse effects and/or the lack of
discomfort or pain associated with injections.
3. Considerations when initiating a DMT in treatment-naïve
patients
A patient's prognostic profile, which includes demographic, clinical,
and MRI characteristics, should be used to guide individual treatment
decisions (Butterworth et al., 2016; Comi et al., 2017). All newly di-
agnosed patients with relapsing MS should start a DMT
(Thompson et al., 2018a). Patients presenting with moderately active
RRMS (at least one relapse in the previous 2 years but fewer than two
relapses in the last year) would be suitable to start a first-line DMT
(Brownlee et al., 2019; Confavreux and Vukusic, 2014; Gajofatto and
Benedetti, 2015). Those with unfavorable prognosis (based on potential
predictors of disease severity such as male gender; a late age at onset;
motor, cerebellar, and sphincter involvement at onset; early progression
of disability; a short inter-attack interval; a high number of early at-
tacks; a high number of MRI lesions, and MRI evidence of brain atrophy
[Bergamaschi, 2007; Ziemann et al., 2011]) and with highly active
disease (at least two relapses in the last year) should start a high effi-
cacy second-line DMT (Gajofatto and Benedetti, 2015).
Recent treatment guidelines also recommend that physicians as-
certain and consider the patient's preferences for efficacy, safety, route
of administration, co-morbidities, lifestyle, cost, family planning,
common adverse effects, and tolerability when initiating a DMT (Rae-
Grant et al., 2018). Choosing an appropriate DMT should be a shared
decision between the patient and physician (MS in the 21st Century
Table 4
Adverse events from phase 3 trials of injectable DMTs and teriflunomide 14 mg.
DMT Triala Adverse events with incidence >10% in any treatment group
IFNβ-1b IFNB Multiple Sclerosis Study (1993) (The IFNB Multiple
Sclerosis Study Group, 1993)
Injection site reactions, inflammation at injection site, fever, myalgia, flu-like symptoms, chills,
sweating, malaise
IFNβ-1a IM The Multiple Sclerosis Collaborative Research Group
Studyb (1996) (Jacobs et al., 1996)
Headache, flu-like symptoms, muscle aches, nausea, fever, asthenia, chills, diarrhea
IFNβ-1a SC PRISMS (1998) (PRISMS Study Group, 1998) Headache, flu-like symptoms, injection site reactions, fatigue
EVIDENCE (2002) (Panitch et al., 2002) Injection site reaction and inflammation, flu-like symptoms
Peg-IFNβ-1a ADVANCE (2014) (Calabresi et al., 2014b)
(NCT00906399)
Injection site erythema, influenza-like illness, pyrexia, headache, MS relapse, myalgia, chills,
injection site pain, asthenia, back pain, injection-site pruritus, nasopharyngitis, arthralgia, fatigue,
pain in extremity
GA Phase 3 study (Johnson et al., 1995) Injection site reactions, transient self-limited systemic reaction (including flushing, chest tightness,
plus dyspnea, palpitations or anxiety)
GA GALA (2013) (Khan et al., 2013) (NCT01067521) Injection site erythema, nasopharyngitis, injection site pain, headache
Teriflunomide TEMSO (2011) (O'Connor et al., 2011) (NCT00134563) Nasopharyngitis, headache, diarrhea, fatigue, elevated ALT level,c nausea, hair thinning or
decreased hair density, influenza, back pain, urinary tract infection, pain in arms or legs
TOWER (2014) (Confavreux et al., 2014) (NCT00751881) ALT increase, hair thinning, headache, nasopharyngitis, diarrhea, fatigue, nausea, upper respiratory
tract infection, urinary tract infection
AEs with incidence >10% in any treatment group.
AE, adverse event; ALT, alanine aminotransferase; DMT, disease modifying therapy; GA, glatiramer acetate; IFN-β, interferon beta; IM, intramuscular; MS, multiple
sclerosis; IFNβ-1a, pegylated interferon beta-1a; SC, subcutaneous.
a Year refers to year of study publication
b Publication reports symptoms seen in >10% of total population and at least 5% higher in treatment group than in placebo group
c Elevated levels were reported as AEs by the investigators.
Table 5
Prospective, randomized head-to-head studies in relapsing MS for injectable DMTs or teriflunomide.
Trial DMTs Outcome
EVIDENCE (Panitch et al., 2002) IFNβ-1a SC TIW vs IFNβ-1a IM weekly IFNβ-1a SC TIW demonstrated superior efficacy in the number of relapse-free
patients (p=0.0005) and active MRI lesions (p<0.001) (N=677)
CombiRx (Lublin et al., 2013)
(NCT00211887)
IFNβ-1a IM weekly + GA 20 mg SC daily vs
IFNβ-1a IM weekly or GA 20 mg SC daily
The combination was significantly better than IFNβ-1a alone in reducing the risk of
relapse and superior to either agent alone in reducing new lesion activity and
accumulation of total lesion volume. GA was significantly better than IFNβ-1a in
reducing the risk of relapse. The combination was no better than either agent alone
in reducing disability worsening
BECOME (Cadavid et al., 2009)
(NCT00176592)
IFNβ-1b every other day vs GA daily No difference in relapses or MRI outcomes (N=75)
BEYOND (O'Connor et al., 2009)
(NCT00099502)
IFNβ-1b 250 µg or 500 µg every other day vs
GA daily
No difference in relapse rate, EDSS progression, and MRI outcomes (N=2244)
INCOMIN (Durelli et al., 2002) IFNβ-1b every other day vs IFNβ-1a IM weekly IFNβ-1b demonstrated superior efficacy on risk of relapse (p=0.03) and MRI
outcomes (p<0.0003) (N=188)
REGARD (Mikol et al., 2008)
(NCT00078338)
IFNβ-1a SC TIW vs GA daily No difference in time to first relapse and no significant differences for MRI
outcomes, except IFNβ-1a-treated patients had significantly fewer enhancing
lesions (p=0.0002) (N=764)
TENERE (Vermersch et al., 2014)
(NCT00883337)
Teriflunomide daily vs IFNβ-1a SC TIW No difference in the primary outcome of time to failure (first appearance of
confirmed relapse or permanent treatment discontinuation for any cause); and no
difference in ARR (secondary outcome) between teriflunomide 14 mg and IFNβ-1a
SC (N=324)
ARR, annualized relapse rate; DMT, disease modifying therapy; EDSS, Expanded Disability Status Scale; GA, glatiramer acetate; IFNβ, interferon beta; IM, in-
tramuscular; MRI, magnetic resonance imaging; MS, multiple sclerosis; RRMS, relapsing remitting multiple sclerosis; SC, subcutaneous; TIW, three-times weekly.
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Steering Group et al., 2018). Studies on patient preference in treatment
decisions have shown heterogeneity of preferences. In some cases, pa-
tients most valued symptom control, in other cases, patients prioritized
delaying disability, and in yet other cases, patients focused on safety
and avoiding AEs. Overall, patients preferred oral administration to
injections, particularly frequent injections (Garcia-Dominguez et al.,
2016; Lebrun et al., 2018; Mansfield et al., 2016; Poulos et al., 2016).
One independent study found patients with MS placed more importance
on DMT monthly out-of-pocket costs and mode of administration than
AEs or efficacy (Hincapie et al., 2017).
Injectable DMTs and teriflunomide have been shown to be effica-
cious in treatment-naïve patients. In the IFNβ-1a studies, significant
reductions in ARR and time to confirmed disability worsening com-
pared with placebo were observed (Jacobs et al., 1996; PRISMSStudy
Group, 1998). While IFNβ-1b and GA studies demonstrated significant
reductions in ARR versus placebo, neither demonstrated significant
reductions in confirmed disability worsening (The IFNB Multiple
Sclerosis Study Group, 1993; Zwibel, 2006). A post-hoc analysis of the
TEMSO and TOWER trials demonstrated a significant reduction in ARR
and a non-significant reduction in the probability of disability wor-
sening with teriflunomide 14 mg compared with placebo in treatment-
naïve patients (Freedman et al., 2018a). Efficacy in patients with CIS
has also been demonstrated in placebo-controlled trials of IFNβ treat-
ments (REFLEX, BENEFIT, CHAMPS, ETOMS (Comi et al., 2012;
Comi et al., 2001; Jacobs et al., 2000; Kappos et al., 2007)), as well as
GA (PreCISe [NCT00666224] (Comi et al., 2009) and teriflunomide
(TOPIC (Miller et al., 2014)).
4. Considerations for patients switching from injectable DMTs
4.1. When and why to switch
Treatment guidelines recommend considering a DMT switch when a
patient shows breakthrough disease activity, assuming the patient has
been on the DMT long enough for the treatment to take full effect and is
adherent to their therapy (Montalban et al., 2018; Rae-Grant et al.,
2018). In the case of breakthrough disease activity on first-line therapy,
the patient should switch to a more potent, high-efficacy DMT.
Guidelines also recommend considering switching DMT for patients
experiencing AEs that negatively influence adherence, or who report
intolerable discomfort with injections or injection fatigue, as these are
also common reasons for poor adherence (Rae-Grant et al., 2018). In-
jection fatigue is generally defined as a waning commitment to continue
with the prescribed injectable treatment and can result from a number
of factors such as side effects, perceived lack of efficacy, anxiety/fear or
“needle phobia”, or depression (Crawford et al., 2014).
In patients experiencing side effects or tolerability issues, a switch to
a DMT within the same efficacy class should be considered (Desai et al.,
2018). Data comparing adherence rates between injectable and oral
DMT classes are limited. One retrospective database claims study found
that patients on injectable DMTs whose most common side effect was
injection site reactions were less likely to be adherent compared with
patients on oral DMTs or infusible DMTs (Higuera et al., 2016).
4.2. Efficacy and treatment satisfaction in patients switching from an
injectable DMT to teriflunomide
Results of a study using MSBase registry data (N=792) examined
patients with stable disease activity on IFNβ/GA who switched to fin-
golimod, DMF, or teriflunomide predominantly due to lack of tolerance
and/or convenience, and found no evidence of disease reactivation
within the first 6 months of switching, compared with patients who
remained on IFNβ/GA (Spelman et al., 2016). A study comparing re-
lapse activity between patients who remained on injectable DMTs and
patients who switched due to tolerability issues to teriflunomide or
DMF, found that switchers had a lower risk of relapse (HR 0.43,
p=0.048) or any disease activity (HR 0.55, p=0.035) compared with
patients who remained on injectable therapy (Saraceno et al., 2019). In
a post-hoc analysis of the pooled phase 3 TEMSO and TOWER studies,
teriflunomide 14 mg was associated with reductions in ARR and risk of
disability worsening across all subgroups defined by prior DMT ex-
posure in the previous 2 years (≥2 prior DMTs, 1 prior DMT, or no
prior DMT) compared with placebo (Freedman et al., 2018b). In the
real-world Teri-PRO study, patients who switched to teriflunomide
from an injectable DMT had statistically significant increases in treat-
ment satisfaction across all four TSQM domains (effectiveness, side
effects, convenience, and global satisfaction) after 48 weeks
(Coyle et al., 2018). In the real-world TAURUS-MS I study, patients who
switched to teriflunomide 14 mg from another DMT predominantly due
to disease worsening, convenience, intolerance to prior mode of ad-
ministration, or AEs demonstrated a decrease in relapses by Month 12
that was sustained at Month 24, with mean Expanded Disability Status
Scale scores remaining low and stable (Kallmann et al., 2019).
4.3. Clinical guidance for patients switching from an injectable DMT
There are several important factors to consider when counseling or
monitoring a patient switching from an injectable to teriflunomide.
Before initiating a switch to teriflunomide, the local label should
always be followed. The authors recommend a complete blood count, a
screen for latent tuberculosis with a tuberculin skin test or blood test for
mycobacterium tuberculosis infection, liver function tests, and blood
pressure measurements be taken. Liver function and blood pressure
should also be monitored monthly in the US (Sanofi Genzyme, 2019),
every 2 weeks in Europe (European Medicines Agency, 2018), for the
first 6 months and then regularly thereafter with continued treatment.
Because teriflunomide is contraindicated in pregnancy, counseling the
patient on family planning, including the need to practice effective
contraception, and carrying out a pregnancy test before switching is
also advised.
No wash out period is necessary. Teriflunomide has been evaluated
as an add-on therapy to IFNβ and GA in two phase 2 trials. Both doses of
teriflunomide and placebo were evaluated over 48 weeks in patients
already receiving a stable dose of IFNβ-1a or IFNβ-1b (Freedman et al.,
2012) and in patients already receiving GA (Freedman et al., 2015). The
frequency of treatment-related AEs was low across all arms in both
trials, demonstrating that an immediate initiation of teriflunomide,
without any wash out period, can be performed.
The most successful switches from injectable to oral DMTs are
usually those initiated due to needle fatigue or AEs. Although switching
generally has a positive impact on a patient's QoL, and risk of disease
activity is low after switching, it is essential for the HCP to reinforce the
importance of treatment adherence, and discuss with the patient any
potential AEs and how they can be managed.
5. Discussion and conclusions
Teriflunomide, GA, and IFNβ have all demonstrated significant re-
ductions in relapse rate compared with placebo in phase 3 trials, with
reassuring long-term safety data. Significant reductions in time to
confirmed disability worsening were seen for teriflunomide and the
various IFNβ-1a drug products, but not for IFNβ-1b nor GA. These
DMTs have acceptable safety profiles, but tolerability varies. Studies
have demonstrated high patient satisfaction and patient preference for
daily, oral administration with teriflunomide, which is the only ap-
proved oral DMT to have demonstrated a significant benefit on dis-
ability across two separate placebo-controlled, pivotal phase 3 trials of
patients with relapsing forms of MS. These findings are further sup-
ported by teriflunomide's significant treatment effect on BVL in the post-
hoc SIENA analysis of the TEMSO MRI data (Radue et al., 2017).
Slowing of BVL may have important clinical implications affecting
treatment decisions, with several clinical trials now demonstrating an
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effect of DMTs in reducing BVL (De Stefano et al., 2014). In clinical
practice, it may therefore be important to consider the potential impact
of a therapy on reducing BVL. In addition, DMT-mediated slowing of
gray matter loss may also be of relevance given its association with
disability, including cognitive decline (Messina and Patti, 2014).
Limitations of this review include the inability to make direct
comparisons across the different studies due to dissimilarities in study
design and the fact that the trials described span a period of more than
20 years. Over that time, the patient population of relapsing MS trials
has shifted, and baseline patient characteristics are not always com-
parable among these studies. In addition, the methodologies and out-
come measures used varied among the different trials. Lastly, the scope
of this review was limited to a handful of DMTs for relapsing MS and is
not a comprehensive guide to choosing a DMT. More treatment options
are available, including high-efficacy infusible treatments and other
oral treatments.
When initiating or switching a DMT, decision-making should be
shared between the patient and physician to select the most appropriate
therapy. It is important to consider patient factors including prognostic
indicators, patient preferences, adherence, and convenience, to identify
suitable options for each patient. It is important to treat patients early
in the MS disease course, and to monitor them closely to ensure sub-
optimal response or low treatment adherence are detected promptly.
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